Recruiting clinical trials in CH

Vous quittez maintenant le site Web de ScienceAmgen.ch et vous êtes redirigé vers un autre site Web d'AMGEN.

Vous quittez maintenant le site Web de ScienceAmgen.ch et vous êtes redirigé vers un autre site Web d'AMGEN.

Vous quittez maintenant le site Web ScienceAmgen.ch
AMGEN n'assume aucune responsabilité pour le contenu du site Web du fournisseur tiers respectif.

Retourner Continuer

back button

Efavaleukin alfa
(AMG 592)

IL-2 mutein Fc fusion protein
Phase 2
Monotherapy
Indication
Ulcerative Colitis
A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis
Amgen protocol ID 20170104
Clinical Trial Card
Status Switzerland
Recruiting
Centers, Principal investigators:
KSSG, S. Brand ✉︎
USZ, L. Biedermann ✉︎
Intesto BE, F. Seibold ✉︎
Inselspital, B. Misslewitz ✉︎
NTC04987307
Rocatinlimab
(AMG 451)

anti-OX40 Antibody
Phase 3
Combination therapy
+ topical corticosteroids/
topical calcineurin inhibitors
Indication
Atopic dermatitis
rocket-shuttle
A Phase 3, randomized, 24-week, placebo-controlled, double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Combination with Topical Corticosteroids and/or Topical Calcineurin Inhibitors in Adult Subjects with Moderate-to-severe Atopic Dermatitis
Amgen protocol ID 20210144
Clinical Trial Card
Status Switzerland
Recruiting
Centers, Principal investigators:
KSSG, A. Cozzio ✉︎
USZ, C. Lang ✉︎
Insel, D. Simon ✉︎
CHUV, T. Caplanusi ✉︎
HUG, E. Laffitte ✉︎
NCT05724199